Published in Nature on June 18, 2015
Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. Nature (2016) 2.86
SC83288 is a clinical development candidate for the treatment of severe malaria. Nat Commun (2017) 1.41
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. Nat Rev Microbiol (2017) 1.38
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Sci Transl Med (2015) 1.29
Pausing on Polyribosomes: Make Way for Elongation in Translational Control. Cell (2015) 1.06
Codon identity regulates mRNA stability and translation efficiency during the maternal-to-zygotic transition. EMBO J (2016) 0.96
High-Throughput Assay and Discovery of Small Molecules that Interrupt Malaria Transmission. Cell Host Microbe (2015) 0.92
Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor. Sci Rep (2016) 0.92
The PfAlba1 RNA-binding protein is an important regulator of translational timing in Plasmodium falciparum blood stages. Genome Biol (2015) 0.87
Luciferase-Based, High-Throughput Assay for Screening and Profiling Transmission-Blocking Compounds against Plasmodium falciparum Gametocytes. Antimicrob Agents Chemother (2016) 0.85
Transmission-blocking activity is determined by transmission-reducing activity and number of control oocysts in Plasmodium falciparum standard membrane-feeding assay. Vaccine (2016) 0.84
The Malaria Parasite's Lactate Transporter PfFNT Is the Target of Antiplasmodial Compounds Identified in Whole Cell Phenotypic Screens. PLoS Pathog (2017) 0.84
Screening out irrelevant cell-based models of disease. Nat Rev Drug Discov (2016) 0.83
A semi-automated luminescence based standard membrane feeding assay identifies novel small molecules that inhibit transmission of malaria parasites by mosquitoes. Sci Rep (2015) 0.83
The Power of Sophisticated Phenotypic Screening and Modern Mechanism-of-Action Methods. Cell Chem Biol (2016) 0.82
High-Throughput Luciferase-Based Assay for the Discovery of Therapeutics That Prevent Malaria. ACS Infect Dis (2016) 0.81
Combinatorial Genetic Modeling of pfcrt-Mediated Drug Resistance Evolution in Plasmodium falciparum. Mol Biol Evol (2016) 0.81
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds. PLoS One (2016) 0.80
Recent advances in malaria genomics and epigenomics. Genome Med (2016) 0.79
Identification of Plasmodium falciparum specific translation inhibitors from the MMV Malaria Box using a high throughput in vitro translation screen. Malar J (2016) 0.78
Phenotypic Screens in Antimalarial Drug Discovery. Trends Parasitol (2016) 0.78
A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria. ACS Infect Dis (2016) 0.78
Recent advances in the biology and drug targeting of malaria parasite aminoacyl-tRNA synthetases. Malar J (2016) 0.78
Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature (2016) 0.77
Discovery of Dual-Stage Malaria Inhibitors with New Targets. Antimicrob Agents Chemother (2015) 0.77
Evolution of Fitness Cost-Neutral Mutant PfCRT Conferring P. falciparum 4-Aminoquinoline Drug Resistance Is Accompanied by Altered Parasite Metabolism and Digestive Vacuole Physiology. PLoS Pathog (2016) 0.76
An inter-laboratory comparison of standard membrane-feeding assays for evaluation of malaria transmission-blocking vaccines. Malar J (2016) 0.76
Malaria: Hitting all stages of the parasite life cycle. Nat Rev Microbiol (2015) 0.75
Current therapies and future possibilities for drug development against liver-stage malaria. J Clin Invest (2016) 0.75
In vitro evaluation of imidazo[4,5-c]quinolin-2-ones as gametocytocidal antimalarial agents. Bioorg Med Chem Lett (2016) 0.75
An ex-vivo maturation assay for testing antimalarial sensitivity of rodent malaria parasites. Antimicrob Agents Chemother (2016) 0.75
Malaria: Hitting all stages of the parasite life cycle. Nat Rev Drug Discov (2015) 0.75
The mRNA-bound proteome of the human malaria parasite Plasmodium falciparum. Genome Biol (2016) 0.75
Transcriptomics and proteomic studies reveal acaricidal mechanism of octadecanoic acid-3, 4 - tetrahydrofuran diester against Sarcoptes scabiei var. cuniculi. Sci Rep (2017) 0.75
Next-generation antimicrobials: from chemical biology to first-in-class drugs. Arch Pharm Res (2015) 0.75
Genetic diversity of next generation antimalarial targets: A baseline for drug resistance surveillance programmes. Int J Parasitol Drugs Drug Resist (2017) 0.75
Extensive Shared Chemosensitivity between Malaria and Babesiosis Blood-Stage Parasites. Antimicrob Agents Chemother (2016) 0.75
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy. J Med Chem (2016) 0.75
Selective inhibition of apicoplast tryptophanyl-tRNA synthetase causes delayed death in Plasmodium falciparum. Sci Rep (2016) 0.75
Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling. PLoS Med (2016) 0.75
Expanding the antimalarial toolkit: Targeting host-parasite interactions. J Exp Med (2016) 0.75
Epigenetic assays for chemical biology and drug discovery. Clin Epigenetics (2017) 0.75
Translational regulation in blood stages of the malaria parasite Plasmodium spp.: systems-wide studies pave the way. Wiley Interdiscip Rev RNA (2016) 0.75
Managing intellectual property to develop medicines for the world's poorest. Nat Rev Drug Discov (2017) 0.75
Alternatives to currently used antimalarial drugs: in search of a magic bullet. Infect Dis Poverty (2016) 0.75
Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways. Antimicrob Agents Chemother (2016) 0.75
Proteases as Antimalarial Targets: Strategies for Genetic, Chemical, and Therapeutic Validation. FEBS J (2017) 0.75
A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature (2013) 11.03
A proteomic view of the Plasmodium falciparum life cycle. Nature (2002) 10.65
Spiroindolones, a potent compound class for the treatment of malaria. Science (2010) 5.94
Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet (2013) 5.22
Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev (2011) 5.15
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature (2012) 4.37
High efficiency transfection of Plasmodium berghei facilitates novel selection procedures. Mol Biochem Parasitol (2005) 3.95
A research agenda for malaria eradication: drugs. PLoS Med (2011) 3.90
Efficient site-specific integration in Plasmodium falciparum chromosomes mediated by mycobacteriophage Bxb1 integrase. Nat Methods (2006) 3.32
Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci U S A (2011) 3.23
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science (2011) 3.07
Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proc Natl Acad Sci U S A (2011) 2.83
Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob Agents Chemother (2008) 2.77
Targeting Plasmodium PI(4)K to eliminate malaria. Nature (2013) 2.49
The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med (2012) 2.42
Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Malar J (2008) 2.41
Designing the next generation of medicines for malaria control and eradication. Malar J (2013) 2.25
Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. ChemMedChem (2008) 1.94
A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes. PLoS One (2008) 1.92
P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action. PLoS One (2012) 1.80
Two crystal structures demonstrate large conformational changes in the eukaryotic ribosomal translocase. Nat Struct Biol (2003) 1.69
Ribosome clearance by FusB-type proteins mediates resistance to the antibiotic fusidic acid. Proc Natl Acad Sci U S A (2012) 1.62
Elongation factor 2 as a novel target for selective inhibition of fungal protein synthesis. J Biol Chem (1998) 1.53
Male and female Plasmodium falciparum mature gametocytes show different responses to antimalarial drugs. Antimicrob Agents Chemother (2013) 1.52
Quantitative measurement of Plasmodium-infected erythrocytes in murine models of malaria by flow cytometry using bidimensional assessment of SYTO-16 fluorescence. Cytometry A (2009) 1.41
Translation elongation factor 2 is part of the target for a new family of antifungals. Antimicrob Agents Chemother (1998) 1.30
The life and death of translation elongation factor 2. Biochem Soc Trans (2006) 1.23
A high-throughput assay for the identification of malarial transmission-blocking drugs and vaccines. Int J Parasitol (2012) 1.17
A framework for assessing the risk of resistance for anti-malarials in development. Malar J (2012) 1.09
Using genetic methods to define the targets of compounds with antimalarial activity. J Med Chem (2013) 1.06
Transmission-blocking interventions eliminate malaria from laboratory populations. Nat Commun (2013) 1.06
Species-specific inhibition of fungal protein synthesis by sordarin: identification of a sordarin-specificity region in eukaryotic elongation factor 2. Microbiology (2001) 0.94
Lead clinical and preclinical antimalarial drugs can significantly reduce sporozoite transmission to vertebrate populations. Antimicrob Agents Chemother (2014) 0.88
Interaction of apicoplast-encoded elongation factor (EF) EF-Tu with nuclear-encoded EF-Ts mediates translation in the Plasmodiumfalciparum plastid. Int J Parasitol (2010) 0.87
Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. Nature (2016) 2.86
Nucleophilic catalysis of acylhydrazone equilibration for protein-directed dynamic covalent chemistry. Nat Chem (2010) 1.07
Current challenges and trends in the discovery of agrochemicals. Science (2013) 1.04
Mutagenesis and functional studies with succinate dehydrogenase inhibitors in the wheat pathogen Mycosphaerella graminicola. PLoS One (2012) 0.93
Identification of inhibitors of the Leishmania cdc2-related protein kinase CRK3. ChemMedChem (2011) 0.90
From on-target to off-target activity: identification and optimisation of Trypanosoma brucei GSK3 inhibitors and their characterisation as anti-Trypanosoma brucei drug discovery lead molecules. ChemMedChem (2013) 0.87
A broad analysis of resistance development in the malaria parasite. Nat Commun (2016) 0.84
The design and synthesis of potent and selective inhibitors of Trypanosoma brucei glycogen synthase kinase 3 for the treatment of human african trypanosomiasis. J Med Chem (2014) 0.81
Achiral oligoamines as versatile tool for the development of aspartic protease inhibitors. Bioorg Med Chem (2008) 0.77
Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature (2016) 0.77
The potential of P1 site alterations in peptidomimetic protease inhibitors as suggested by virtual screening and explored by the use of C-C-coupling reagents. ChemMedChem (2006) 0.75
Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. Sci Transl Med (2017) 0.75